Catheter Precision, Inc. · AMEX:VTAK
Catheter Precision — Investor Presentation (March 2025)
25 slides from Catheter Precision's investor presentation, Mar 12, 2025
Slide 1: Investor Presentation March 2025
(Wsrecicion INVESTOR PRESENTATION March 2025 Ym “d - ! NYSEAM: VTAK
Slide 2: Forward-Looking Statements and Estimates
FORWARD-LOOKING STATEMENTS (Asetheter AND ESTIMATES ‘and ‘Secuttes Act of 193 1934, respectivel “safe harbor legal, c "may, “wil intend," "should, "could," “woul,” expect," "plan i r pre addition, ou it 1 therel vn cathetrprecisoncom | NYSEAM: VTAK
Slide 3: Forward-Looking Statements and Estimates (Continued)
FORWARD-LOOKING STATEMENTS (Asetheter AND ESTIMATES (Continued) The , thatthe results ie on may be more to fund our proposed enter into a strategi ‘we willnot be are able to achieve our Our may depend lucts, and may enter into additional joint marktingagromens, that wl reduce cur revenues from produ
Slide 4: About Catheter Precision
ABOUT CATHETER PRECISION (aan iv] Improve Patient Outcomes (v} Reduce Healthcare Costs iv) Enhance Hospital Productivity Mission Statement Catheter Precision is a U.S.-based medical device company advancing cardiac arrhythmia treatment through innovation and physician collaboration. Our mission is t
Slide 5: Successful Track Record of CEO David Jenkins
(srecision SUCCESSFUL TRACK RECORD OF CEO DAVID JENKINS cae 'EPMedSystems ——_‘-— Arrhythmia SrMeisyems || eevee eaten CEO & Chairman Founder & CEO Founder & President + + + Implantable device for obesity Focused Focused > > > Sold to St. Jude for $93 million Sold to Medtronic for $267 million Produc
Slide 6: Key Statistics
KEY STATISTICS Corporate Highlights Current Product Portfolio: LockeT and VIVO", providing cost savings, improved patient outcomes, and streamlined clinical workflows. Large & Growing Market Opportunity: Well-positioned to compete in the multi-billion- dollar global market across catheter ablation,
Slide 7: Global Electrophysiology Market
GLOBAL ELECTROPHYSIOLOGY MARKET = (520257 Precision The EP market is projected to grow to $15.1 bn by 2028 Population growth, increasing rates of heart diseases and the rising cost of healthcare are driving growth in the electrophysiology and catheter ablation markets. ‘The global electrophysioiogy
Slide 8: Product Portfolio
(sreczisn PRODUCT PORTFOLIO Vi 7 Wo & LockeT View Into Ventricular Onset A cost-effective solution for site closure with suture retention, ensuring efficient hemostasis while prioritizing patient comfort FDA Registered ‘Commercial launch in 2024 v' Non-invasive 3D imaging system that enables physici
Slide 9: LockeT Suture Retention Device
((srecision LockeT Suture Retention Device A cost-effective solution for site closure at the access point with suture retention providing efficient hemostasis and improving patient comfort.
Slide 10: Current Challenges in Vascular Closure
CURRENT CHALLENGES IN VASCULAR CLOSURE (srecision @ Prolonged Bed Rest & Delayed Discharge: Traditional manual compression requires extended immobilization (4-8 hours), delaying patient esas discharge and reducing hospital procedure volume @ High Resource Utilization: Manual compression requires sig
Slide 11: LockeT: Advancing Vascular Closure in a Growing Market
(srecision LockeT Advancing Vascular Closure in a Growing Market Vascular Closure Devices Market was valued at USD $1.9 bn in 2023 and is poised to grow at an 8.4% CAGR from 2024 to 20301 Meeting the Demand for Next-Generation Solutions + Rising AF Cases: 33 million people + Scalable: Designed for l
Slide 12: Product Overview
(srecision PRODUCT OVERVIEW The device is placed at the end of the procedure, allowing for hemostasis to occur at the access site. IN THE LAB i / lal ‘sheaths. Clean site via standard protocol in Locke’. the handle 90" IN RECOVERY e Unlock the Locke by releasing te handle the access site. Follow Feg
Slide 13: LockeT Product Segments
LOCKET PRODUCT SEGMENTS Locket's Broad Range of End Users Ambulatory Hospitals Accs) LockeT Other Care Diagnostic Facilities Centers wwrw.catheterprecision.com | NYSEAM: VTAK KEY PROCEDURE TYPES Interventional Cardiology (srecision VERSATILE APPLICATIONS * Diagnostic Interventions T Interventional R
Slide 14: LockeT Market Penetration & Growth Strategy
(srecision LockeT MARKET PENETRATION & GROWTH STRATEGY Growing LockeT , Building Clinical Utilization Global Market Expansion Recent New Customers vn cathetrprecisoncom | NYSEAM: VTAK lll
Slide 15: VIVO Non-invasive 3D Mapping System
(Werecision Vier Non-invasive 3D Mapping System www.catheterprecision.com NYSEAM: VTAK
Slide 16: Product Overview
(srecision PRODUCT OVERVIEW le Enhance Procedural Efficiency for Ventricular / Arrhythmias with Patient Specific Solutions Non-invasive 3D imaging system + Provides a 3D matrix model of the heart on a computer monitor with a superimposed activation map + Enables physicians to accurately target the a
Slide 17: Ventricular Ablation Market
VENTRICULAR ABLATION MARKET (aan The Ventricular Ablation Market is Growing Faster than the Overall Electrophysiology Market + Tachycardia ablation is forecasted to grow at 14.5 % CAGR through 2032, a faster rate than the broader electrophysiology and catheter 14.5% ablation markets.* G + Over a ten
Slide 18: The Challenge in Mapping Ventricular Arrhythmias
THE CHALLENGE IN MAPPING VENTRICULAR ARRHYTHMIAS [>] Elusive Arrhythmia Origins: Standard ECG can mislead physicians to the wrong location © Complex & Multiple Morphologies: PVCs often appear with varying shapes; spotting and precisely targeting each is difficult. © long, Trial-and-Error Procedures:
Slide 19: The VIVO Solution
The VIVO™ SOLUTION Provides Precise Ventricular Insight 99.5%! accurate in ventricular onset localization Improves Workflow Increases potential ablation success prior to the start of a procedure? (srecision Maximizes Efficiency 27%? shorter procedure time Patient Specific Inputs Localizes multiple a
Slide 20: Proven Sales Leadership & Team Expanding Global Presence
PROVEN SALES LEADERSHIP & (aan TEAM EXPANDING GLOBAL PRESENCE Marie-Claude HEEEINES Recent New Customers Increasing adoption of Catheter Precision products in hospitals and surgical centers, growing pipeline of evaluations. ‘HE UNIvERstTY Of TENNESSEE MEDICAL CENTER ge) EISENHOWER OVERLAND PARK MEDI
Slide 21: Strategic Growth Through Acquisition of PeriKard LLC
(srecision STRATEGIC GROWTH THROUGH ACQUISITION OF PERIKARD LLC In January 2025, acquired PeriKard LLC, a development-stage company focused on improving physician access to the pericardial space. Strengthens Catheter Precision's footprint in the ventricular therapeutic market with an improved needle
Slide 22: Medtech M&A: Strong Valuations in Vascular & Electrophysiology
MEDTECH M&A: STRONG VALUATIONS (srecision IN VASCULAR & ELECTROPHYSIOLOGY Recent M&A activity highlights strong valuations for iated vascular and ies, reinforcing the high value placed on catheter-based closure solutions and next-generation ablation systems. Vascular 5 Intervention Vascular Closure
Slide 23: LockeT Clinical Strategy Snapshot
LockeT CLINICAL STRATEGY SNAPSHOT LockeT clinical studies aim to demonstrate ease of use, faster hemostasis, early ambulation, same-day discharge, and improved patient comfort. The LockeT II study, enrolling over 130 patients, compares LockeT to standard procedure closures. Additional studies will e
Slide 24: VIVO Clinical Strategy Snapshot
VIVO CLINICAL STRATEGY (Asetheter SNAPSHOT VIVO continues to demonstrate accuracy, efficiency, and clinical impact, supported by numerous studies, publications, and case reports. A multi-center EU Registry has been completed, and ongoing research focuses on complex VT management, procedural efficien
Slide 25: ((srecision
((srecision NYSEAM: VTAK www.catheterprecision.com
Catheter Precision — Investor Presentation (March 2025) on 6ix